Enhanced human monocyte cytotoxicity by platelet-activating factor

Immunology. 1988 Aug;64(4):715-8.

Abstract

The capacity of platelet-activating factor (PAF) to enhance human monocyte cytotoxicity for WEHI 164 cells was examined. Spontaneous monocyte cytotoxicity was 24 +/- 2% (mean +/- SEM, n = 9). Preincubation of monocytes with 1 pM-1 nM PAF for 18 hr significantly enhanced cytotoxicity in a dose-related manner, whereas less enhancement was observed at PAF concentrations above 1 nM. Maximal PAF-induced cytotoxicity was 68 +/- 6%, which was similar to that induced by optimal concentrations of tumour necrosis factor (TNF) and interferon-gamma. The specific PAF antagonist kadsurenone inhibited PAF-induced cytotoxicity but not TNF-induced cytotoxicity. The inactive PAF analogues lysoPAF and enantioPAF did not increase monocyte cytotoxicity. Two observations suggest that TNF mediates PAF-induced cytotoxicity: specific anti-TNF antibodies inhibited PAF-induced cytotoxicity toward WEHI 164 cells, and PAF did not enhance cytotoxicity to TNF-resistant cells. PAF represents a distinct class of phospholipid monocyte activators that increase monocyte cytotoxicity by TNF-dependent mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Benzofurans / pharmacology
  • Cells, Cultured
  • Cytotoxicity, Immunologic*
  • Dose-Response Relationship, Immunologic
  • Humans
  • Isomerism
  • Lignans*
  • Monocytes / immunology*
  • Platelet Activating Factor / analogs & derivatives
  • Platelet Activating Factor / antagonists & inhibitors
  • Platelet Activating Factor / pharmacology*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Benzofurans
  • Lignans
  • O-deacetyl platelet activating factor
  • Platelet Activating Factor
  • Tumor Necrosis Factor-alpha
  • kadsurenone